Literature DB >> 12430878

Novel biologically based therapies for multiple myeloma.

Nikhil C Munshi1, Teru Hideshima, Dharminder Chauhan, Paul Richardson, Kenneth C Anderson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12430878     DOI： 10.1007/bf03165281

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  9 in total

Review 1.  Multiple Myeloma. Advances in disease biology: therapeutic implications.

Authors:  K C Anderson
Journal:  Semin Hematol       Date:  2001-04       Impact factor: 3.851

2.  The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

Authors:  T Hideshima; P Richardson; D Chauhan; V J Palombella; P J Elliott; J Adams; K C Anderson
Journal:  Cancer Res       Date:  2001-04-01       Impact factor: 12.701

3.  Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications.

Authors:  Nicholas Mitsiades; Constantine S Mitsiades; Vassiliki Poulaki; Dharminder Chauhan; Paul G Richardson; Teru Hideshima; Nikhil C Munshi; Steven P Treon; Kenneth C Anderson
Journal:  Blood       Date:  2002-06-15       Impact factor: 22.113

4.  Antitumor activity of thalidomide in refractory multiple myeloma.

Authors:  S Singhal; J Mehta; R Desikan; D Ayers; P Roberson; P Eddlemon; N Munshi; E Anaissie; C Wilson; M Dhodapkar; J Zeddis; B Barlogie
Journal:  N Engl J Med       Date:  1999-11-18       Impact factor: 91.245

5.  Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.

Authors:  T Hideshima; D Chauhan; Y Shima; N Raje; F E Davies; Y T Tai; S P Treon; B Lin; R L Schlossman; P Richardson; G Muller; D I Stirling; K C Anderson
Journal:  Blood       Date:  2000-11-01       Impact factor: 22.113

6.  NF-kappa B as a therapeutic target in multiple myeloma.

Authors:  Teru Hideshima; Dharminder Chauhan; Paul Richardson; Constantine Mitsiades; Nicholas Mitsiades; Toshiaki Hayashi; Nikhil Munshi; Lenny Dang; Alfredo Castro; Vito Palombella; Julian Adams; Kenneth C Anderson
Journal:  J Biol Chem       Date:  2002-02-28       Impact factor: 5.157

7.  Clinical activity of arsenic trioxide for the treatment of multiple myeloma.

Authors:  N C Munshi; G Tricot; R Desikan; A Badros; M Zangari; A Toor; C Morris; E Anaissie; B Barlogie
Journal:  Leukemia       Date:  2002-09       Impact factor: 11.528

8.  Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model.

Authors:  Richard LeBlanc; Laurence P Catley; Teru Hideshima; Suzanne Lentzsch; Constantine S Mitsiades; Nicholas Mitsiades; Donna Neuberg; Olga Goloubeva; Christine S Pien; Julian Adams; Deepak Gupta; Paul G Richardson; Nikhil C Munshi; Kenneth C Anderson
Journal:  Cancer Res       Date:  2002-09-01       Impact factor: 12.701

9.  Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment.

Authors:  Toshiaki Hayashi; Teru Hideshima; Masaharu Akiyama; Paul Richardson; Robert L Schlossman; Dharminder Chauhan; Nikhil C Munshi; Samuel Waxman; Kenneth C Anderson
Journal:  Mol Cancer Ther       Date:  2002-08       Impact factor: 6.261
  9 in total
  2 in total

1.  Myelomatous meningitis: a case report.

Authors:  Yoshiharu Kusano; Yasuhito Terui; Noriko Nishimura; Masahiro Yokoyama; Kyoko Ueda; Kiyohiko Hatake
Journal:  Int J Hematol       Date:  2016-05-27       Impact factor: 2.490

Review 2.  New frontiers in the treatment of multiple myeloma.

Authors:  Janice Jin Hwang; Irene M Ghobrial; Kenneth C Anderson
Journal:  ScientificWorldJournal       Date:  2006-12-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.